BioVaxys Technology Corp: Advancing Global Health Through Innovative Vaccines
BioVaxys Technology Corp, a Canadian biotechnology company, is making significant strides in the development of vaccines and immunotherapy products. Headquartered in Vancouver, British Columbia, the company has been a key player in life sciences research and development since its incorporation in 2001. With a strong focus on addressing global health challenges, BioVaxys is dedicated to transforming the treatment and prevention of infectious diseases and advancing immunotherapy for cancer.
Financial Overview
As of September 1, 2025, BioVaxys Technology Corp’s stock closed at CAD 0.03 on the Canadian National Stock Exchange. The company’s market capitalization stands at CAD 8,802,756. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of CAD 0.08 on November 4, 2024, and a low of CAD 0.02 on August 10, 2025.
Innovative Solutions for Global Health
BioVaxys is renowned for its innovative approach to tackling infectious diseases and cancer. The company’s flagship product, VaxMite, is a novel vaccine currently in development to combat Plasmodium falciparum, the most lethal form of malaria. This vaccine represents a significant advancement in the fight against malaria, a disease that continues to pose a major global health threat.
In addition to VaxMite, BioVaxys is exploring the potential applications of its technology platform across various medical and healthcare fields. The company’s commitment to innovation is evident in its ongoing research and development efforts aimed at creating new immunotherapy approaches for cancer treatment.
Mission and Vision
BioVaxys Technology Corp’s mission is to revolutionize the way infectious diseases are treated and prevented. By developing cutting-edge vaccines and immunotherapy products, the company aims to address some of the most pressing health challenges of our time. With a focus on global health, BioVaxys is dedicated to improving patient outcomes and enhancing the quality of life for individuals affected by infectious diseases and cancer.
As BioVaxys continues to advance its research and development initiatives, the company remains committed to its vision of transforming healthcare through innovation and scientific excellence.